A comparative study between Etomidate and Thiopentone was carried out on 100 healthy female patients scheduled for post-partum abdominal sterilization under epidural analgesia.
Etomidate, a new non-barbiturate intravenous hypnotic, is a carboxylated imidazole derivative Experimental (J anssen et al. 1971) and clinical (Doenicke et al. 1973 , Morgan et al. 1975 , Gooding and Corssen 1976 studies have revealed that it possesses certain advantages over the commonly used intravenous induction agents. Onset of and recovery from anaesthesia are rapid, the cardiovascular and respiratory systems are minimally depressed and there is no detectable histamine release.
A clinical trial was undertaken to evaluate the induction characteristics of etomidate using thiopentone as a standard.
MATERIALS AND METHOD

Drug solutions
Etomidate: The parenteral preparation of 2 mg per ml of the sulphate salt in isotonic and buffered aqueous solution in 10 ml ampoules (pH 3.4).
Thiopentone: A freshly prepared 2.5% solution was employed (pH 11).
Patient material
One hundred healthy, Chinese, female patients scheduled for post-partum abdominal sterilization under epidural analgesia were selected for the double-blind trial. Half the patients received etomidate while the o~her half received thiopentone as supplement. The order of drug administration was randomized by drawing lots from a box.
Anaesthetic technique
No premedication was prescribed. An intravenous infusion of 5 % dextrose in water via a 21 gauge teflon cannula was set up in the dorsum of the hand. Lumbar epidural analgesia was then initiated using a standardized technique and 25 ml of 1.5 % lignocaine with 1 in 400,000 adrenaline. When the block was established, a standard dose of either etomidate 20 mg or thiopentone 250 mg was injected ~hrough the infusion tubing over a period of 30 seconds. The same anaesthetist was responsible for the intravenous injection in all patients and the other investigator, not knowing the drug dispensed, carried out the evaluation.
Patients who did not attain a satisfactory level of sensory blockade (dermatone 10 and above) and those who developed tremors after epidural were excluded from the study.
Assessment
At the commencement of injection, the patient was engaged in conversation until sleep supervened. The induction time was considered DO H. H. CHIU AND W. K. VAN as the period from the time of injection to the time when the patient was unable to respond to commands. The time at which eyelash reflex disappeared was also noted. The respiratory rate, blood pressure and pulse rate were measured before and immediately after induction and every five minutes thereafter until completion of surgery. The patient was closely observed for occurrence of side-effects during induction, throughout the period of unconsciousness and during recovery. Record was also made of the time when the patient opened her eyes on command, when she was able to answer simple questions and when she was fully orientated to time and space.
The patient was interviewed the next day and the injection site examined for signs of thrombophlebitis. She was questioned on the occurrence of post-anaesthetic complications and was asked to recall events in the operating theatre. Her view on having the same agent for induction in the future was also ascertained.
RESULTS
The mean age, body weight and height of patients in the two study groups are presented in Table I . The differences between the two groups are not statistically significant.
Etomidate produced sleep rapidly. Its induction time ranged from 20 seconds to 55 seconds with a mean of 32.8 seconds; these values were comparable to those for thiopentone (Table 2 ). An unusual feature of etomidate was the marked delay in the loss of eyelash reflex (Table 3) ; in 3 patients the eyelash reflex remained unobtunded throughout the period of unconsciousness. The types and incidence of side-effects at induction are tabulated in Table 4 . Local intolerance to etomidate was common. 28 patients (56%) experienced pain along the vein during injection; in 16, the pain was distressing. In the thiopentone group, only 2 patients voiced complaint whilst 5 others admitted having had slight discomfort during injection.
TABLE 4
Side e/Jects at induction 
r nvoluntary muscle movements occurred in 34 etomidate patients (68 % ). 16 had generalized convulsive movements; in 10 of these, the contractions were confined to one or more group of muscles and consisted of jerky limb movements; in the remaining 8, there were only fine tremors. The involuntary movements usually appeared towards the end of injection; they were transient and subsided after about 30 seconds. External stimulations such as in-flation of the sphygnomanometer cuff or moving the mandible sometimes evoked recurrence of these movements. Following thiopentone injection, 4 patients developed jerky limb movements while 2 patients had fine tremors. Etomidate induction was also associated with increase in muscle tone. Jaw tone was maintained in 44 patients with bruxism present in 3 of them. Mandibular support for ensuring airway patency was often not required. In the thiopentone group, 17 patients had no impairment of masseter tone and 1 patient had bruxism. Pupillary dilatation was prevalent among vhe etomidate patients while the effect of thiopentone on pupillary size was equivocal. The incidence of other excitatory phenomena such as nystagmus, hiccup, coughing, retching and laryngospasm were not significantly different between the two drugs.
26 patients in the etomidate group developed transient respiratory irregularities at induction. In 19, these consisted of a short period of hyperventilation followed by a brief apnoeic phase; in 6, there was tachypnoea; the remaining patient had Cheyne-Stokes breavhing. Respiratory rhythm returned to basal level by 2 minutes after induction, and subsequently there was a slight increase in respiratory rate which persisted throughout the operation. In the thiopentone group, 23 patients developed apnoea, which was not preceded by hyperventilation and was of longer duration, and there were two instances of Cheyne-Stokes breavhing. The respiratory rate at two minutes after induction was lowered slightly but returned to pre-induction value by seven minutes.
Analysis of the changes in blood pressure and pulse rate reveals that etomidate produced an initial minimal decrease but a subsequent increase in systolic pressure, a rise in diastolic pressure and a slight fall in the pulse rate. The differences from control were statistically significant for systolic pressure at the 12th and 17th minute after induction and for diastolic pressure from 7th minute onward. On the other hand, thiopentone caused depression of systolic pressure to a greater extent but this returned to basal level by the 7th minute, a slight decrease in diastolic pressure initially with subsequent rise and a small initial rise followed by a fall in pulse rate. All these changes, however, were statistically not significantly different from control.
Values for sleep duration were slightly higher for etomidate than thiopentone, but the differences were statistically not significant (Table  5 ). The majority of etomidate patients regained consciousness after 10 to 15 minutes while for the thiopentone group, most of them were awake after 5 to 10 minutes. Table 6 lists the incidence of post-anaesthetic sequelae of the two drugs. There was a higher incidence of dizziness, delirium, nausea and vomiting, headache and thrombophlebitis among the etomidate patients but a lower incidence of drowsiness; the differences were statistically not significant. 9 patients who received etomidate could not recall events immediately prior to induction compared to 13 in the thiopentone group. For etomidate, the patient acceptance rate was 90% and the anaesthetist acceptance rate was 58%, whereas for thiopentone the acceptance rate was 94 % in both instances. The objectionable features of etomidate were involuntary muscle movements and pain during injection. 
DISCUSSION
Controlled clinical trial is generally considered the best means to obtain therapeutic knowledge of a new drug (Atkins 1966) . Thiopentone 2.5 % in a fixed dosage of 250 mg was chosen as a standard of reference as this is routinely employed for anaesthetic induction of fit patients. The equipotent dose of etomidate is approximately 20 mg (Doenicke et al. 1973, Ghoneim and Yamada 1977) . Calculated on body weight basis (thiopentone 3.5 mg/ kg, etomidate 0.3 mg/ kg), the dosage used for this trial was high for the majority of our patients. These drugs were given as supplement to epidural analgesia in order that duration of drug action could also be evaluated.
From the results of this study, etomidate appears to be a safe and effective induction agent with a rapid sleep onset time and brief duration of action. Like the conventional rapid acting intravenous anaes~hetic induction agent thiopentone, it consistently produced sleep within one minute of injection. The persistence of the eyelash reflex following etomidate induction could possibly be due to clonic contractions of the obicularis oculi muscles and invalidates its use for assessing level of consciousness.
The cardiovascular system remained remarkably stable. Our finding of a slight decrease in pulse rate is at variance with that of Holdcroft et al. (1976) and Kay (1976) , who reported a significant increase in pulse rate; this could be attributed to the fact that our patients were not premedicated with atropine. Investigations on the effects of etomidate on cardiovascular functions revealed an increase in cardiac output and stroke volume with a decrease in systemic vascular resistance and myocardial oxygen consumption (Kettler et al. 1974 , Weymar et al. 1974 ) and insignificant impairment of myocardial con tractility (Doenicke et al. 1974) . The inability of etomidate to produce detectable histamine release may exempt it from allergic cardiovascular collapse and thereby further contribute tc) cardiovascular stability.
Etomidate unlike thiopentone appears to stimulate rather than depress respiration. The respiratory rate was higher than the control rate and the brief period of apnoea was preceded by hyperventilation. Morgan et al. ( 1977) held the view that the apnoea was brought about by breath holding as a result of involuntary muscle movements and increased muscle tone.
The high incidence of injection pain and the frequent occurrence of generalized myoclonia will preclude the wide acceptance of etomidate as an anaesthetic induction agent. Holdcroft et al. (1976) observed that premedication with a narcotic and injection of the drug into larger veins significantly reduced the frequency of pain during injection and involuntary muscle movements. Efforts are being made to minimize the occurrence of these undesirable features by the prior administration of fentanyl 0.05 -0.1 mg and the use of a new solvent 35 % propylene glycol for etomidate (J ansen Pharmaceutica 1976) . Further clinical studies will be required to assess the value of these measures.
